Bavarian Nordic hunting for RSV partners: "If the firm is too small, we might as well consider launching ourselves"

Bavarian Nordic’s recent deal in China has some pundits guessing that more partnerships are on the way. Even so, the company’s CFO Henrik Juuel says if the bidders aren’t the right size, it might be in Bavarian’s best interest to commercialize its RSV vaccine itself.
Photo: Bavarian Nordic / PR
Photo: Bavarian Nordic / PR
by CHRISTIAN BUNDGAARD, translated by daniel pedersen

As the ink dries on the deal Bavarian Nordic just signed with a Shanghai-based partner, a question emerges: Having found a partner in China, what will the Danish pharmaceutical firm do with its RSV vaccine candidate in the US and Europe?

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading